Kvika Asset Management

PLAIO is an AI-powered planning platform designed specifically for the pharmaceutical industry, aiming to transform how companies manage their supply chain and operations. The platform replaces traditional, spreadsheet-based planning methods with advanced artificial intelligence, machine learning, and real-time data analytics, thereby optimizing demand, manufacturing, and purchasing processes. PLAIO seamlessly integrates with existing ERP systems, enhancing data-driven decision-making, improving forecast accuracy, and streamlining planning workflows. It is tailored for small to medium-sized pharmaceutical manufacturers and virtual pharma companies, allowing them to reduce risks, lower costs, and increase efficiency in a highly regulated and competitive environment. Key features include visual and capacity planning, advanced constraint calculations, what-if analysis, and AI-based automation, enabling clients to conduct agile manufacturing operations and achieve precise product output.

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory disorders by enhancing epithelial barrier integrity. This barrier is crucial for the proper functioning of human skin, lung tissue, the intestinal tract, and genitalia. Disruption of this barrier is linked to chronic inflammation and various diseases. The company is creating a proprietary portfolio of orally available macrolide drug candidates, which aim to serve as first-in-class disease-modifying therapeutics for chronic respiratory conditions and other significant unmet medical needs. EpiEndo's lead candidate, EP395, is designed to be the first oral, non-antibiotic macrolide that strengthens barriers and reduces inflammation in patients with chronic obstructive pulmonary disease (COPD) and other inflammatory airway diseases.